[HTML] nature.com

[HTML][HTML] γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - Nature, 2023 - nature.com
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …
被引用次数：108 相关文章
[PDF] tudelft.nl

[PDF][PDF] γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - Nature, 2023 - pure.tudelft.nl
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - Nature, 2023 - research.tudelft.nl
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga… - … weekly journal of …, 2023 - repository.tudelft.nl
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …
[PDF] universiteitleiden.nl

[PDF][PDF] Haar,. an de

NL Vries - Veninga, V., Chalabi, M., I sselstei n …, 2023 - scholarlypublications …
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga… - …, 2023 - pubmed.ncbi.nlm.nih.gov
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - paper.sciencenet.cn
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

NL de Vries, J van de Haar, V Veninga, M Chalabi… - Nature, 2023 - europepmc.org
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …
[HTML] nih.gov

[HTML][HTML] γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - Nature, 2023 - ncbi.nlm.nih.gov
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

NL de Vries, J van de Haar, V Veninga, M Chalabi… - …, 2023 - ui.adsabs.harvard.edu
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB) …